National Health Investors (NHI) has been on a downward trend, losing 10.2% over the past four weeks. However, the stock is now in oversold territory, and there is strong agreement among analysts that the company will report better earnings than previously predicted, indicating a potential turnaround.

Healthpeak Properties, Inc. (DOC) is well-positioned to benefit from its diversified healthcare real estate assets, particularly its lab and continuing care retirement community (CCRC) portfolios. However, it faces competition and challenges from a high-interest rate environment.

Does National Health Investors (NHI) have what it takes to be a top stock pick for momentum investors? Let's find out.

In the latest quarter, 4 analysts provided ratings for National Health Investors (NYSE:NHI), showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 0 2 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.0, a high estimate of $69.00, and a low estimate of $58.00. Observing a 7.14% increase, the current average has risen from the previous average price target of $60.67. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive National Health Investors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target James Feldman Wells Fargo Raises Overweight $69.00 $63.00 Michael Lewis Truist Securities Raises Hold $58.00 $55.00 Richard Anderson Wedbush Raises Outperform $66.00 $64.00 Juan Sanabria BMO Capital Announces Outperform $67.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National Health Investors. This information provides a ...Full story available on Benzinga.com

While the top- and bottom-line numbers for National Health Investors (NHI) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Innovative Industrial Properties (IIPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in FFO estimate revisions for the stock doesn't suggest further strength down the road.

Industrial Logistics Properties Trust (ILPT) delivered FFO and revenue surprises of 7.69% and 1.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

National Health Investors (NYSE:NHI) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 2 0 0 0 2M Ago 0 2 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated National Health Investors and provided 12-month price targets. The average target is $64.5, accompanied by a high estimate of $69.00 and a low estimate of $58.00. This upward trend is evident, with the current average reflecting a 11.69% increase from the previous average price target of $57.75. Analyzing Analyst Ratings: A Detailed Breakdown In examining recent analyst actions, we gain insights into how financial experts perceive National Health Investors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Michael Lewis Truist Securities Raises Hold $58.00 $55.00 Richard Anderson Wedbush Raises Outperform $66.00 $64.00 Juan Sanabria BMO Capital Announces Outperform $67.00 - Richard Anderson Wedbush Raises Outperform $64.00 $57.00 Connor Siversky Wells Fargo Raises Overweight $63.00 $55.00 Omotayo Okusanya Deutsche Bank Announces Buy $69.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to National Health Investors. This information offers ...Full story available on Benzinga.com

Technology stocks are experiencing surge in investment similar to dot-com boom of the late 90s. Click here for 2 individual bonds which are now easy to purchase.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy . Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector. PotlatchDeltic Corporation (NASDAQ: PCH) Dividend Yield: 4.07% RBC Capital analyst Matthew McKellar reiterated a Sector Perform rating with a price ...

BMO Capital Markets analyst Juan C. Sanabria upgraded National Health Investors, Inc. (NYSE:NHI) from Market Perform to Outperform, maintaining the price forecast of $67. Sanabria sees the potential for multiple expansions for the company, with upside to earnings driven primarily by SHOP and acquisitions. Acquisitions also represent an opportunity with $150 million of debt firepower, given National Health Investors’ low leverage (4.4X net debt/EBITDA). The analyst keeps a more constructive stance on the company’s SHOP portfolio given the recent strong 4Q23 occupancy and a ...Full story available on Benzinga.com

National Health Investors (NYSE:NHI) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for National Health Investors, presenting an average target of $65.75, a high estimate of $69.00, and a low estimate of $63.00. This upward trend is evident, with the current average reflecting a 17.41% increase from the previous average price target of $56.00. Decoding Analyst Ratings: A Detailed Look The analysis of recent analyst actions sheds light on the perception of National Health Investors by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target John Kim BMO Capital Announces Outperform $67.00 - Richard Anderson Wedbush Raises Outperform $64.00 $57.00 Connor Siversky Wells Fargo Raises Overweight $63.00 $55.00 Omotayo Okusanya Deutsche Bank Announces Buy $69.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to National Health Investors. This information provides a snapshot of how ...Full story available on Benzinga.com